Product Liability

  • December 19, 2006

    Deaths Prompt Warnings On Rituxan

    The U.S. Food and Drug Administration and the drug makers are warning the public that two patients who have taken non-Hodgkins lymphoma and rheumatoid arthritis drug Rituxan have died from a rare nervous system disease.

  • December 18, 2006

    Eli Lilly Disputes New York Times Report

    Eli Lilly & Co. downplayed the risks of its schizophrenia and bipolar disorder drug Zyprexa while also encouraging doctors to prescribe the drug for patients that had neither condition, according to company marketing documents.

  • December 14, 2006

    Merck: Vioxx Litigation Strategy Is Working

    Merck & Co. Inc. has notched another win in a personal injury suit stemming form the use of the painkiller Vioxx, a development the company is touting as a vindication of its strategy to tackle thousands of Vioxx product liability claims individually. But an attorney for the plaintiff says it’s too early for Merck to be crowing.

  • December 13, 2006

    Jury Mulls Arguments In Latest Vioxx Trial

    A New Orleans jury in the twelfth civil trial over Merck & Co.’s ill-fated Vioxx headed into deliberations on Wednesday after lawyers representing the pharmaceutical giant called into question the credibility of a Tennessee man who had a heart attack in 2003 after taking the painkiller.

  • December 12, 2006

    Accusations Fly Over Contraceptive Patch

    The legal woes keep piling up for Ortho-McNeil Pharmaceutical Co. The manufacturer of the popular birth-control patch was back in court Tuesday to face a wrongful death lawsuit brought by a 26-year-old woman and a mass action brought on behalf of 55 women who claim the contraceptive caused blood clots and other serious illnesses.

  • December 7, 2006

    Johnson & Johnson Faces Stent Suit

    A Florida man has sued Johnson & Johnson for failing to alert him to the potential dangers of drug-coated stents, which are used to treat heart disease in angioplasties.

  • December 7, 2006

    Lawyers Eye Broad Impact From IPO Case

    A U.S. appeals court’s decision this week to unbundle class actions in litigation against top investment banks could have consequences for wide swaths of the law, lawyers agree.

  • December 4, 2006

    Paxil Caused Birth Defects, Lawsuit Claims

    Just a month after GlaxoSmithKline PLC agreed to pay $63.8 million to settle claims in a class action lawsuit over its antidepressant drug Paxil, the U.K. drug maker is facing another slew of lawsuits over birth defects allegedly caused by the drug.

  • December 1, 2006

    Sanofi-Aventis Continues To Face Trouble Over Ketek

    A Tennessee woman has sued Sanofi-Aventis alleging that her liver was damaged while she took the antibiotic Ketek, adding to the legal problems the company faces over the drug.

  • November 30, 2006

    Drug-Coated Stents Face Further Scrutiny

    With a Food and Drug Administration advisory panel set to examine drug-coated stents at an upcoming meeting, a report has shown that the devices increase the risk of life-threatening blood clots in patients with coronary artery disease by four or five times that of bare-metal stents.

  • November 29, 2006

    Court Refuses To Toss Claims Against Medtronic

    A federal judge in Minnesota has denied a motion for summary judgment by medical device maker Medtronic Inc., allowing hundreds of cases brought by personal injury claimants over Medtronic’s implantable cardiac defibrillators to move forward.

  • November 29, 2006

    Merck Downplayed Vioxx Risks, Doctor Testifies

    Merck & Co. told its salespeople not to tell doctors about a study by a Harvard Medical School professor that found that Vioxx increased the risk of heart attacks, a researcher testified Tuesday in a trial in New Orleans.

  • November 27, 2006

    Wyeth, Others Face New Hormone Replacement Suit

    A woman has filed a suit against Wyeth and other drug companies, claiming that her hormone replacement treatment caused her breast cancer.

  • November 27, 2006

    Judge Rules Vioxx Claims Should Be Tried Separately

    Pharmaceutical giant Merck & Co Inc. will not face a nationwide class action suit over wrongful death and personal injury claims stemming from the use of Merck’s blockbuster painkiller Vioxx, a federal judge in New Orleans has ruled.

  • November 20, 2006

    Private Funding For Class Actions Clears In Australia

    A recent decision by Australia’s High Court has cleared the way for private lending companies to fund class action lawsuits, setting the stage for an increase in follow-on litigation in antitrust and securities disputes, lawyers say.

  • November 16, 2006

    Asarco Wants Environmental Expert To Assess Liabilities

    Asarco LLC has asked the federal bankruptcy judge overseeing its Chapter 11 case for permission to retain an expert consultant to help estimate the mining and smelting company’s environmental liabilities, expected to total billions of dollars.

  • November 15, 2006

    FDA Eyes Sanofi Antibiotic Over Safety Concerns

    The U.S. Food and Drug Administration has asked a joint panel of outside experts to turn the spotlight on a bronchitis treatment marketed by pharmaceutical giant Sanofi-Aventis SA amid concerns over the antibiotic’s possible link to severe liver problems and several deaths.

  • November 15, 2006

    Jury Gives Merck Another Vioxx Win

    A federal jury said Wednesday that Merck & Co. wasn’t liable for a man’s heart attack, handing the drug company a victory in its fight over withdrawn arthritis drug Vioxx.

  • November 13, 2006

    Vioxx Class Action Approved In Quebec

    A Quebec court has given its stamp of approval for the first personal-injury class action in North America against Merck & Co. over the painkiller Vioxx.

  • November 10, 2006

    FDA To Up Postmarket Regulation Of Medical Devices

    In a bid to quell escalating concerns over medical device regulation, the U.S. Food and Drug Administration on Thursday jumped into action, revealing plans to bolster the way it monitors the safety of products such as stents, pacemakers, and implantable defibrillators after they reach the marketplace.